Jazz Pharmaceuticals
JAZZ
303 hedge funds and large institutions have $8.03B invested in Jazz Pharmaceuticals in 2017 Q3 according to their latest regulatory filings, with 32 funds opening new positions, 119 increasing their positions, 102 reducing their positions, and 45 closing their positions.
17% more repeat investments, than reductions
Existing positions increased: 119 | Existing positions reduced: 102
2.45% more ownership
Funds ownership: 88.9% → 91.36% (+2.5%)
3% less capital invested
Capital invested by funds: $8.31B → $8.03B (-$275M)
5% less funds holding
Funds holding: 319 → 303 (-16)
29% less first-time investments, than exits
New positions opened: 32 | Existing positions closed: 45
48% less call options, than puts
Call options by funds: $37.8M | Put options by funds: $73.1M
55% less funds holding in top 10
Funds holding in top 10: 11 → 5 (-6)
Top Buyers
| 1 |
Goldman Sachs
New York
|
+$54.9M |
| 2 |
Schroder Investment Management Group
London,
United Kingdom
|
+$53.7M |
| 3 |
TCIM
TIAA CREF Investment Management
New York
|
+$53.4M |
| 4 |
SIG
Senator Investment Group
New York
|
+$45.4M |
| 5 |
WRF
Waddell & Reed Financial
Overland Park,
Kansas
|
+$45.2M |
Top Sellers
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$49.2M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
-$42.1M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$37.5M |
| 4 |
BlackRock
New York
|
-$35M |
| 5 |
CCM
Cadian Capital Management
New York
|
-$32.3M |
JAZZ Hedge Fund Activity: Q3 2017 in Review
303 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Jazz Pharmaceuticals (JAZZ) for Q3 2017, worth a combined $8.03B — down 3.3% from $8.31B a quarter earlier.
Sellers outnumbered buyers: 45 funds closed out of JAZZ and 32 opened new positions — a net loss of 13 holders — while 102 trimmed existing stakes and 119 added.
The largest buyer was Goldman Sachs, adding an estimated $54.9M. The largest seller was Adage Capital Partners, cutting an estimated $49.2M.
- 303 institutional investors held Jazz Pharmaceuticals (JAZZ) as of Q3 2017, down from 319 in Q2 2017.
- Funds reported $8.03B of Jazz Pharmaceuticals stock for Q3 2017, down 3.3% quarter-over-quarter.
- 32 funds opened new Jazz Pharmaceuticals positions in Q3 2017 and 45 closed out, a net change of -13 holders.
- The largest Jazz Pharmaceuticals buyer in Q3 2017 was Goldman Sachs, an estimated $54.9M added.
- The largest Jazz Pharmaceuticals seller in Q3 2017 was Adage Capital Partners, an estimated $49.2M sold.
Based on aggregated 13F filings for Q3 2017.